

Special Issue

Nanocarriers-Based Antimicrobial Drug Delivery

Message from the Guest Editor

Combating microbial infections is challenging due to the rapid development of multi-drug resistance. Microbial diseases can be contagious or infectious, resulting in short or chronic and long-lasting illnesses. Nanocarriers—polymer/lipid-based, liposomes, micelles, metal-based, silica, fullerenes, dendrimers, zeolites, quantum dots, hydrogels and composites—have been explored for antipathogenic, microbicidal, or microbiostatic properties in various microbial infections, including those arising from biofilms. Nevertheless, nanocarriers for intracellular or extracellular infections need to be designed appropriately to target specific microbes, alleviate the resistance of the drug-pathogen interaction and toxicity and disrupt biofilms as well as increase the scope in theranostics and cosmeceuticals. In this Special Issue, manuscripts, both original research and reviews, concerning nanocarrier-based approaches for antimicrobial drug delivery-related areas of interest in human and veterinary medicine and in the food and agriculture industry are welcome.

Guest Editor

Dr. Anisha D'Souza

Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA

Deadline for manuscript submissions

closed (15 April 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/136882

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)